{"id":"W4387811473","doi":"10.1016/j.annonc.2023.09.1846","title":"660MO First-in-human study of SGN-B7H4V, a B7-H4-directed vedotin ADC, in patients with advanced solid tumors: Preliminary results of a phase I study (SGNB7H4V-001)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"ca_institutions":"Ottawa Hospital","funders":"Loxo Oncology; Genentech; Seagen; Relay Therapeutics; Aileron Therapeutics; Jazz Pharmaceuticals; Exelixis; Daiichi Sankyo Europe; Eli Lilly and Company; Daiichi-Sankyo; Amgen","keywords":"Medicine; Neutropenia; Tolerability; Internal medicine; Febrile neutropenia; Response Evaluation Criteria in Solid Tumors; Phases of clinical research; Pharmacokinetics; Gastroenterology; Adverse effect; Oncology; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001626633,0.001816918,0.001689963,0.0004438634,0.0007305894,0.001480247,0.0008908894,0.001392141,0.004027318],"category_scores_gemma":[0.0005264904,0.0007171869,0.001476676,0.0004176563,0.00111166,0.0007848679,0.0003218686,0.004101131,0.001641584],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001274193,"about_ca_system_score_gemma":0.002003689,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004570572,"about_ca_topic_score_gemma":0.007340596,"domain_scores_codex":[0.9995121,0.0001889562,0.00001189097,0.00005488999,0.00003880338,0.0001932941],"domain_scores_gemma":[0.9994045,0.00007289956,0.00005557941,0.00006198238,0.00003865185,0.0003663833],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4147444,0.172953,0.01365295,0.0009575405,0.002248308,0.001360608,0.000885261,0.006032263,0.1657761,0.0009148852,0.02060245,0.1998722],"study_design_scores_gemma":[0.1951706,0.7407709,0.01567985,0.00006220468,0.0008017254,0.001020478,0.0001784295,0.002106744,0.02870286,0.0003735535,0.01507181,0.00006078811],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9833651,0.003281865,0.001577673,0.0008311045,0.0002889581,0.001818186,0.003215444,0.0002699588,0.005351599],"genre_scores_gemma":[0.9780628,0.003111256,0.001937287,0.0009432962,0.0001929421,0.001474741,0.004887663,0.000122465,0.009267461],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004570572,"threshold_uncertainty_score":0.01347268,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07154427690141917,"score_gpt":0.4382774052844848,"score_spread":0.3667331283830656,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}